For all press and media enquiries please contact mediarelations@chiesi.com
The latest available statistics reveal that, during the first six months of the year, overall revenues increased by 11.6% vs the first 6 months of 2018 These results confirm 2019 to be a year characterised by significant growth for the Group which has recently celebrated a key strategic objective:…
Certified B Corporations meet the highest standards of verified social and environmental performance, transparency and accountability. Chiesi Group receives the B Corp certification from B Lab, a leading global sustainability non-profit body, in recognition of its corporate sustainability practices.…
Paolo Chiesi receives the award for his long-standing commitment to vital treatment of the lungs of premature babies. The ceremony will take place on 10 May in Stockholm City Hall Stockholm May 10, 2019 – Chiesi Farmaceutici, an international research-focused healthcare Group (Chiesi Group), is…
Chiesi, an international research-focused healthcare Group (Chiesi Group), was awarded yesterday at the EURORDIS Black Pearl ceremony with the Company Award for Innovation. The EURORDIS Black Pearl Award is an annual event held in Brussels to recognise the outstanding achievements and exceptional…
A Benefit Corporation is a new legal form of business enterprise which represents a paradigm shift and is an expression of a more evolved vision, incorporating a two-fold purpose into its business objective: in addition to the objective of generating profit it also pursues the goal of making a…
Only 16% of those interviewed believe they may be at risk, even if the disease is considered serious or very serious in almost all cases (95%). On average 36% of those who claim to have heard about COPD make reference to the media (radio and TV in particular) as their main source of information.…
Chiesi, an international research-focused healthcare Group (Chiesi Group), today announced that it has completed the acquisition of 100% of NHCO Nutrition® SAS (NHCO) shares, a French company specialized in food supplements commercialized in pharmacies, currently active in the French market. NHCO…
Protalix grants Chiesi Ex-US rights for PRX-102, a chemically modified version of the recombinant protein alpha-Galactosidase-A protein The agreement includes an initial investment of 25 million dollars, as a reimbursement for research costs incurred by Protalix, an additional up to $20 million in…
Cary, N.C., June 12, 2018 – Chiesi USA (key-A-zee), a specialty pharmaceutical company based in Cary, N.C., and the Italian biotech Holostem Terapie Avanzate S.r.l., announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to an investigational product,…
You are leaving the Chiesi Corp site to access another Chiesi site. Regulatory constraints and medical practices, as well as the information published on the site you are about to visit, may change from one country to another and may not comply with current Italian legislation on the subject.
You are about to leave our website and access an external site. By continuing, you agree to leave our site.
